November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
ESMO 2023 – Lumakras still looks like a colorectal also-ran
And first data with a low dose are particularly unimpressive.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Bristol puts Mirati out of its misery
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
Roche stakes its KRAS claim
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
More doubts swirl around Lumakras
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
